AstraZeneca plots more pipeline deals

After AstraZeneca ($AZN) announced plans to buy Ardea for $1.26 billion, company officials quickly talked up plans to do more deals before the end of the year. Caught with one of the weakest late-stage programs in Big Pharma, AstraZeneca isn't even sticking with its disease focus. Promising drugs that can add some excitement and get the analysts to back off are welcome. "We're building some momentum here in R&D," Martin Mackay, head of research and development, told Bloomberg. "I would be disappointed if we didn't announce further deals by the end of this year. We've taken our hits but we're turning a corner." Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.